Tsui, Judith I.
Akosile, Mary A.
Lapham, Gwen T.
Boudreau, Denise M.
Johnson, Eric A.
Bobb, Jennifer F.
Binswanger, Ingrid A.
Yarborough, Bobbi Jo H.
Glass, Joseph E.
Rossom, Rebecca C.
Murphy, Mark T.
Cunningham, Chinazo O.
Arnsten, Julia H.
Thakral, Manu
Saxon, Andrew J.
Merrill, Joseph O.
Samet, Jeffrey H.
Bart, Gavin B.
Campbell, Cynthia I.
Loree, Amy M.
Silva, Angela
Stotts, Angela L.
Ahmedani, Brian
Braciszewski, Jordan M
Hechter, Rulin C.
Northrup, Thomas F.
Horigian, Viviana E.
Bradley, Katharine A. http://orcid.org/0000-0003-1933-4425
Funding for this research was provided by:
National Institute on Drug Abuse (UG1DA040314, UG1DA040316, U10 DA013714, 5UG1DA013035, UG1-DA015831, UG1DA020024, U10-DA13720)
Article History
Received: 8 April 2020
Accepted: 3 December 2020
First Online: 10 February 2021
Compliance with Ethical Standards
:
: The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
: Dr. Bobbi Jo H. Yarborough has received support through her institution from Syneos Health to conduct FDA-mandated post-marketing research on the risks of opioid analgesic use. Dr. Cynthia Campbell has received research support through her institution from the Industry PMR Consortium, a consortium of companies working together to conduct post-marketing studies required by the Food and Drug Administration that assess known risks related to opioid analgesic use.
Free to read: This content has been made available to all.